Research Information System
JOURNAL OF CLINICAL MEDICINE, vol.12, no.17, pp.196-211, 2023 (SCI-Expanded)
Prognostic nutritional index (PNI), which is calculated using the albumin level reflecting
nutritional status and lymphocyte count reflecting immune status, is useful in showing nutritional
and immunological status related to survival and prognosis in many cancers. In this study, we aimed
to evaluate the biomarker potential and effect of PNI in determining the prognosis of metastatic
castration-sensitive prostate cancer (mCSPC). This retrospective observational study included the
complete data of 108 patients with mCPSC who were treated for at least three months between
1 January 2010, and 1 June 2021. The relationships between cancer-specific survival (CSS), overall
survival (OS), progression-free survival (PFS), and PNI were evaluated. The Kaplan–Meier method
for OS, PFS, and CSS, as well as univariate and multivariate Cox regression models, were used for
the statistical analyses. The median age of 108 patients included in the study was 68.54 (61.05–74.19)
years. A value of 49.75 was determined to be the best cut-off point for the PNI. OS (months) was
found to be significantly lower in patients with low PNI (median: 34.93, 95% CI: 21.52–48.34) than
in patients with high PNI (median: 65.60, 95% CI: 39.36–91.83) (p = 0.016). Patients with high PNI
(median: 48.20, 95% CI: 34.66–61.73) had significantly better CSS (months) than patients with low
PNI (median: 27.86, 95% CI: 24.16–31.57) (p = 0.001). There was no statistically significant difference
in PFS between patients with high PNI values (median: 24.60, 95% CI: 10.15–39.05) and patients with
low PNI values (median: 20.03, 95% CI: 11.06–29.03) (p = 0.092). The PNI is a good predictor of OS
and CSS in patients with mCSPC. The prediction of PFS, albeit showing a trend towards significance,
was not statistically significant, probably due to the small number of cases.